Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.
about
Molecular mimics of the tumour antigen MUC1Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinomaNK cells: key to success of DC-based cancer vaccines?Dendritic cell vaccine against leukemia: advances and perspectives.Promising new strategies for hepatocellular carcinoma.Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells.Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO).Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity.Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).Immunotherapy of hepatocellular carcinoma
P2860
Q28485169-A17E6007-5A16-4828-A251-61CB3D46A4CDQ35107234-AFCCA9D6-3F8F-4287-BAE6-F86B7B37EF76Q35514419-BECDCD43-D05A-43FD-8B15-5D74D145B4AEQ35567765-02C173ED-A4B1-41F2-94A7-7532D8715CBCQ37565482-FB6A6AE4-CDD8-4FEB-BF10-2F13E9FC5C4DQ38036202-B0EF0D47-4D0A-4B3B-A1E1-4DED9402C928Q38210813-C62CBBA8-578F-4C7D-B37D-FD2AFD9DF50FQ38936589-8CD85CCB-CB8C-4865-8411-6F18C9A52210Q47552123-3BC7443B-77F5-4616-BC5A-B9C3F4D057ABQ51201669-02D213B2-5111-4B8A-9AEA-EFACBA4E3163Q54839137-1FB7EDE1-837B-416B-811B-063EBA1980F8Q55008075-572C0494-818D-4105-AD36-18BE0030F8E3Q55291915-BEAE2BA4-11C7-44FE-BC71-46040ED7AF8CQ55709201-08C246A0-42DC-4EA1-B9FD-AB64322BBB05Q56896669-945DCE6B-7418-440E-85A0-EEB6A09EBB35
P2860
Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dendritic cell-based vaccines ...... tocellular carcinoma patients.
@ast
Dendritic cell-based vaccines ...... tocellular carcinoma patients.
@en
type
label
Dendritic cell-based vaccines ...... tocellular carcinoma patients.
@ast
Dendritic cell-based vaccines ...... tocellular carcinoma patients.
@en
prefLabel
Dendritic cell-based vaccines ...... tocellular carcinoma patients.
@ast
Dendritic cell-based vaccines ...... tocellular carcinoma patients.
@en
P2860
P356
P1476
Dendritic cell-based vaccines ...... atocellular carcinoma patients
@en
P2093
Lazar Vujanovic
Sarah M Bray
P2860
P304
P356
10.1155/2011/249281
P577
2011-09-28T00:00:00Z